What is Generate Biomedicines, Inc. 's accounts payable?

Generate Biomedicines, Inc. (GENB) reported accounts payable of $7.62M in Q1 2026.

What does accounts payable mean?

Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.

Generate Biomedicines, Inc. GENB Accounts Payable

Accounts Payable at other companies

RepligenRGEN

$34.66M+28.7%

Loar HoldingsLOAR

$23.89M+69.6%

Cogent Biosciences, Inc.COGT

$13.74M-2.9%

Kymera TherapeuticsKYMR

$12.84M+25.1%

Versant Media Group, Inc. VSNT

$283M+958%

MatsonsMATX

$254.3M-7.2%

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's accounts payable?: Generate Biomedicines, Inc. (GENB) reported accounts payable of $7.62M in Q1 2026.
What does accounts payable mean?: Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.